Cognitive Peptides Compared: Selank, Semax, Dihexa, and Cerebrolysin

These four compounds share a common thread — they all modulate neurotrophic signaling, neuroplasticity, or neuroprotective pathways — but their structural diversity is striking.

Selank is a 7-amino-acid synthetic analogue of tuftsin, a naturally occurring immunopeptide, with an additional Pro-Gly-Pro sequence that dramatically extends its half-life and CNS activity.

Semax is derived from ACTH (adrenocorticotropic hormone) — specifically the 4–7 fragment (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro extension. It was developed in the Soviet Union in the 1980s specifically for brain protection and cognitive enhancement research.

Dihexa is a small molecule peptide derived from Angiotensin IV research at Washington State University. It is an HGF/c-Met agonist with extraordinary synaptogenic potency in animal models — described in the original research as several orders of magnitude more potent than BDNF in driving dendritic spine formation.

Cerebrolysin stands apart structurally — it is not a single molecule but a standardized mixture of low-molecular-weight neuropeptide fragments derived from purified porcine brain protein, designed to mimic the brain's own neurotrophic repair signals.

Selank's primary research domain is anxiolytic activity — it modulates the GABAergic system (similar in target, though not mechanism, to benzodiazepines) without producing the sedation or dependence profiles associated with classical GABA modulators. Russian clinical research has examined Selank in generalized anxiety disorder with positive results.

Where it excels: Anxiety, stress response, and immune-cognitive interaction models. Also studied in learning and memory paradigms where anxiolytic effect is a desirable concomitant variable.

Semax was developed specifically for neurological applications and has been studied extensively in Russia, where it has been approved for clinical use in stroke and cognitive impairment. It is one of the few peptides with both strong preclinical data and meaningful human clinical research.

Where it excels: Cognitive enhancement models, neuroprotection in ischemia, BDNF pathway research, and intranasal CNS delivery models. Also studied in ADHD and depression research contexts in the published literature.

Dihexa occupies a unique position: it is the most synaptogenically potent compound in this group by a wide margin in animal research, but also has the smallest body of published literature. It was discovered relatively recently (2010s) and most research originates from Washington State University.

Where it excels: Synaptogenesis research, Alzheimer's model research, HGF/c-Met pathway studies. The limited but striking published data makes it a high-interest compound for researchers investigating synaptic plasticity.

Cerebrolysin's distinguishing feature is the breadth of its neurotrophic activity — it simultaneously engages BDNF/TrkB, NGF/TrkA, and CNTF receptor pathways. No single-molecule peptide achieves this, which is why Cerebrolysin's clinical research footprint is larger than any compound in this group.

Where it excels: Stroke recovery, Alzheimer's disease research, TBI recovery models. The combination of multi-mechanism activity and substantial clinical evidence makes Cerebrolysin the most translationally relevant compound for neurodegenerative disease research.

Each compound targets distinct primary systems:

For researchers, the mechanistic distinctions determine model selection. Selank for anxiety-cognition interaction research. Semax for BDNF pathway and neuroprotection studies. Dihexa for synaptogenesis and HGF/c-Met pathway research. Cerebrolysin for comprehensive neurotrophic and clinical translation research.

All four compounds are for preclinical and laboratory research use only. No FDA approval for human therapeutic use exists for any compound in this group in the United States. Several have regulatory approval in other countries (Selank, Semax, and Cerebrolysin are approved in Russia; Cerebrolysin is also approved across Europe and Asia).

Purity is critical in CNS research: Endotoxin contamination causes neuroinflammation that confounds any cognitive or neuroprotective endpoint. Verify COA documentation for endotoxin testing before use in neural models.